Study tests safer switch from street CBD to approved drug for kids with severe epilepsy

NCT ID NCT06924827

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best way to switch children with Dravet or Lennox-Gastaut syndrome from artisanal (non-pharmaceutical) cannabidiol to Epidiolex, an FDA-approved CBD medication. About 25 children aged 2 to 18 will gradually increase their Epidiolex dose while reducing their artisanal CBD over two weeks. Researchers will track how many successfully make the switch and continue on Epidiolex for 20 weeks, monitoring side effects and seizure control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Epidiolex (pharmaceutical-grade cannabidiol)
What this could lead to
If successful, this study could provide a safe, step-by-step method for switching children from unregulated CBD products to a consistent, approved medication for seizure control.
What could go wrong
This is a small, early-phase study with only 25 participants, so results may not apply to everyone. Side effects from the switch or differences in dosing could cause problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME (DS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.